PPD inks deal to buy Russian CRO

PPD says it's inked a deal to buy InnoPharm, an independent contract research organization based in Russia. The buyout gives PPD reach into the Russian and Ukrainian markets. "With more than 143 million people in Russia alone, Eastern Europe is a high-growth market for clinical trials and a region PPD has targeted for expansion," said Fred Eshelman, chief executive officer of PPD. InnoPharm employs about 300 people.

- check out the release
- here's the AP report

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.